Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib Monotherapy for PALB2-Mutated Advanced Breast Cancer
NCT04756765Phase 2Withdrawn
- Sponsor
- Stanford University
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of talazoparib in breast cancer, sponsored by Stanford University. Planned start Feb 2023; status: withdrawn.
02
Drugs
talazoparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04756765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04756765.